Business Highlights from the Healthcare Space: Complementary Research on Amphastar Pharma, Can-Fite BioPharma, Nanosphere, Immune Pharmaceuticals and Actinium Pharma
NEW YORK, May 14, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), Can-Fite BioPharma Ltd. (NYSE: CANF), Nanosphere, Inc. (NASDAQ: NSPH), Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), and Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
AMPH Research Report: ( http://get.analystsreview.com/pdf/?c=Amphastar%20Pharmaceuticals&d=14-May-2015&s=AMPH ),
CANF Research Report: ( http://get.analystsreview.com/pdf/?c=Can-Fite%20BioPharma&d=14-May-2015&s=CANF ),
NSPH Research Report: ( http://get.analystsreview.com/pdf/?c=Nanosphere&d=14-May-2015&s=NSPH ),
IMNP Research Report: ( http://get.analystsreview.com/pdf/?c=Immune%20Pharmaceuticals&d=14-May-2015&s=IMNP ),
ATNM Research Report: ( http://get.analystsreview.com/pdf/?c=Actinium%20Pharmaceuticals&d=14-May-2015&s=ATNM ).
============
--
Analyst Update: Earnings Updates, Regulatory Clearance, Strategic Partnerships, and Clinical Trial Updates
U.S. stocks closed virtually flat on Wednesday, amid disappointing monthly retail sales data. The Dow Jones Industrial Average fell 0.04%, to finish at 18,060.49, the S&P 500 edged down 0.03%, to 2,098.48, while the NASDAQ Composite rose modestly by 0.11%, to end the session at 4,981.69. European stocks mostly closed lower on Wednesday, despite positive economic growth data. Germany's DAX 30 declined 1.05%, and France's CAC 40 slipped 0.26%. In contrast, London's FTSE 100 closed 0.23% higher on Wednesday, mainly reflecting upbeat unemployment data. Meanwhile, Asian markets were mixed on Wednesday, amid weaker Chinese economic data. The Shanghai Composite and Hong Kong's Hang Seng were both down on Wednesday, while Japan's Nikkei closed higher.
On March 24, 2015, Amphastar Pharmaceuticals, Inc. reported results for Q4 FY14 and the full-year 2014. For Q4 FY14, the Company reported net revenues of $55.9 million, an increase of 2% from the prior-year period. Cost of revenues for Q4 FY14 were $43.9 million, or 79% of revenues during the quarter, as compared to $35.2 million, or 64% of revenues, for Q4 FY13.
Can-Fite BioPharma Ltd. announced on May 11, 2015, that it has received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The Phase II randomized, double-blind, placebo controlled trial is being conducted in the U.S., Israel, and Europe.
On May 11, 2015, Nanosphere, Inc. reported financial results for Q1 FY15. Revenues for Q1 FY15 rose 41% to $4.6 million, compared to $3.3 million in Q1 FY14. Gross margins increased to 46% in Q1 FY15 from 38% in the prior-year quarter, driven by consumable cost reductions, coupled with lower royalty expenses due to the expiration of certain agreements.
On May 4, 2015, Immune Pharmaceuticals Inc. and STC Biologics announced that the two Companies are entering into a strategic partnership to accelerate the development of NanomAbs, a new generation of Antibody Nanoparticle Conjugates allowing the targeted delivery of chemo-therapeutics. The strategic partnership will leverage research capabilities of STC and Immune.
On April 15, 2015, Actinium Pharmaceuticals, Inc. announced that the first patient was successfully treated with Actimab-A drug candidate in the fourth and last cohort of the ongoing Phase 1/2 trial of Actimab-A. Actimab-A is being developed for newly diagnosed AML patients over the age of 60 ineligible for standard induction chemotherapy.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article